Amgen's Q3 2024 earnings call highlighted robust growth across various therapeutic areas, with strong performance in oncology, rare diseases, and inflammation.  Management expressed confidence in the pipeline, especially with the continued progress of MariTide,  and initiatives like the Phase II study in type 2 diabetes.  Positive data from Phase II trials and upcoming Phase III programs should be key drivers for investor sentiment in the near term.
[1]
